Advances in Antileishmania Drug Agent

Dear Colleagues,

Leishmaniasis is a spectrum of infectious and parasitic diseases caused by protozoa of the genus Leishmania. The World Health Organization categorizes Leishmaniasis as an emerging uncontrolled disease, with about 12 million people infected, and more than 350 million people at risk. Given the groups of people it affects (usually low-income) and the lack of investment in chemotherapy treatment research, Leishmaniasis is considered a Neglected Tropical Disease (NTD). Treatment of leishmaniasis by chemotherapy remains a challenge because of limited efficacy, toxic side effects, and drug resistance. The search for new therapeutic agents from natural sources has been a constant for the treatment of diseases such as leishmaniasis.

This Special Issue on Pharmaceutics aims to gather relevant manuscripts involving basic, translational, and clinical research, and covering various advances in treatment for leishmaniasis. For this research topic, we are inviting interested researchers to share their original research, relevant findings, and review articles in the areas of antileishmanial drug identification, drug combinations, immunotherapy, drug delivery systems, parasite drug resistance; and target identification and validation for tropical protozoan diseases of medical interest.

Prof. Dr. Klinger Antonio Da Franca Rodrigues
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• antileishmanial activity
• visceral leishmaniasis
• tegumentary leishmaniasis
• drug development
• natural products
• synthetic products